News | July 04, 2023
Biocon Biologics' Hulio Biosimilar to Humira now available in the US
The launch of HULIO in the United States is an important milestone for Biocon Biologics
The launch of HULIO in the United States is an important milestone for Biocon Biologics
This request for withdrawal of the two dossiers was made after necessary consultations and receiving guidance from EMA
Despite nearly 20 years of availability, biosimilars show worldwide adoption rate of only 14% in initiative-tracked countries, while reference medicines still represent 86% of biologic
Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio
The successful outcome of this study represents an important milestone in Dr. Reddy's commitment to make highquality biosimilar products more accessible and affordable
Milan is also an important hub for the distribution of pharmaceuticals to the rest of Europe
Roflumilast reduces inflammation in the lungs that leads to chronic obstructive pulmonary disease (COPD)
Following successful completion of full set of clinical studies of proposed rituximab biosimilar candidate DRL_RI, Dr. Reddy’s will now prepare to file in the United States, European Union and other regions
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
Roflumilast Tablets had annual sales of US $248 million in the United States according to IQVIA data
Subscribe To Our Newsletter & Stay Updated
